LMO2 and severe combined immunodeficiency: LMO2 serves as a T‐cell oncogene, recurrently translocated in T‐ALL, and is implicated in leukemogenesis among X‐linked severe combined immunodeficiency (SCID) patients, who received retroviral IL2Rγc gene therapy (Hacein‐Bey‐Abina et al, 2003, 2008; Pike‐Overzet et al, 2007; Howe et al, 2008).